Skip to main content

Table 2 Adverse events

From: A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas

Group Toxicity Grade 3 Grade 4 Total Dose level
Hematologic Thrombocytopenia 3 3 6 4
Neutropenia 5 5 4
Lymphocyte count decreased 1 1 4
White blood cell decreased 1 1 4
Gastrointestinal Lipase increased 3 3 4
ALT increased 3 3 4
Vomiting 3 3 4, 5
Serum Amylase increased 2 2 4
Abdominal pain 1 1 5
Anorexia 1 1 5
AST increased 1 1 4
Stomatitis 1 1 4
Weight loss 1 1 4
Metabolic Hypophosphatemia 6 6 4, 5
Hypokalemia 2 2 4, 5
Hypocalcemia 1 1 4
Hyponatremia 1 1 4
Other Bone infection 1 1 4
  1. Only adverse events (AEs) of Grade ≥ 3 and with attribution of “Possible” or above reported. ALT alanine aminotransferase, AST aspartate aminotransferase, ANC absolute neutrophil count